1st Line Durvalumab in PS 2 NSCLC Patients
Clinical trial NCT03620669 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03620669
- Sponsor
- Swiss Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-04
- Primary completion
- 2023-01-19
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.